REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 218 filers reported holding REATA PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is 0.42 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $1,497,000 | -86.6% | 12,112 | -89.4% | 0.69% | -87.0% |
| Q3 2020 | $11,160,000 | -12.9% | 114,554 | +39.5% | 5.31% | -3.5% |
| Q2 2020 | $12,809,000 | +18.3% | 82,100 | +9.5% | 5.50% | +8.6% |
| Q1 2020 | $10,826,000 | -15.8% | 75,000 | +19.2% | 5.06% | -10.4% |
| Q4 2019 | $12,859,000 | +155.9% | 62,900 | +0.5% | 5.65% | +102.6% |
| Q3 2019 | $5,025,000 | -57.4% | 62,591 | -49.9% | 2.79% | -53.1% |
| Q2 2019 | $11,790,000 | -21.5% | 124,965 | -28.9% | 5.94% | -9.5% |
| Q1 2019 | $15,017,000 | +5.8% | 175,700 | -30.6% | 6.57% | -10.3% |
| Q4 2018 | $14,193,000 | +116.6% | 253,000 | +215.6% | 7.33% | +100.5% |
| Q3 2018 | $6,553,000 | +125.5% | 80,155 | -3.5% | 3.65% | +71.5% |
| Q2 2018 | $2,906,000 | -52.4% | 83,094 | -72.1% | 2.13% | -44.4% |
| Q1 2018 | $6,107,000 | +24.7% | 297,750 | +72.2% | 3.83% | +6.4% |
| Q4 2017 | $4,896,000 | – | 172,897 | – | 3.60% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CPMG Inc | 3,063,567 | $298,453,000 | 49.63% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 150,000 | $14,613,000 | 19.62% |
| Corriente Advisors, LLC | 300,000 | $29,226,000 | 14.82% |
| Prosight Management, LP | 114,554 | $11,160,000 | 5.31% |
| MADDEN SECURITIES Corp | 43,927 | $4,279,000 | 3.18% |
| LBJ Family Wealth Advisors, Ltd. | 30,368 | $2,958,000 | 2.24% |
| Biondo Investment Advisors, LLC | 99,652 | $9,708,000 | 2.10% |
| Cormorant Asset Management, LP | 450,000 | $43,839,000 | 1.69% |
| Duquesne Family Office | 543,901 | $52,987,000 | 1.54% |
| AWH Capital, L.P. | 9,500 | $925,000 | 1.30% |